Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03213691 · OUTCOME

Percentage of Participants With Treatment-related Adverse Events as Accessed by Common Terminology Criteria for Adverse Events (CTCAE) Version (v) 5.0

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) · Source last updated 2025-02-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of patients
Interval / dispersion
95% Confidence Interval
Time frame
From enrollment to the end of treatment, up to 2 years

What was measured

A patient will be counted only once for a given toxicity for the worst grade of that toxicity reported for that patient.

Analysis population: One patient was deemed ineligible by the Study Chair and is excluded from this analysis.

Groups in this outcome

Treatment (Selumetinib)

Patients receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Selumetinib)20

Reported measurements

Source class 1
Values in Percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Selumetinib)90Not reported68.398.8Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        68.3
        upper Limit
        98.8
        value
        90
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
description
A patient will be counted only once for a given toxicity for the worst grade of that toxicity reported for that patient.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Selumetinib)
param Type
NUMBER
population Description
One patient was deemed ineligible by the Study Chair and is excluded from this analysis.
reporting Status
POSTED
time Frame
From enrollment to the end of treatment, up to 2 years
title
Percentage of Participants With Treatment-related Adverse Events as Accessed by Common Terminology Criteria for Adverse Events (CTCAE) Version (v) 5.0
type
SECONDARY
unit Of Measure
Percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice